Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 142

Results For "data"

2046 News Found

PM-JAY public dashboard gets revamped with new features
News | June 07, 2022

PM-JAY public dashboard gets revamped with new features

The dashboard will serve as a single source of truth for public and PM-JAY stakeholders providing comprehensive view of scheme’s progress


FDA publishes ANP’s polymeric drug excipient DMF
Drug Approval | June 06, 2022

FDA publishes ANP’s polymeric drug excipient DMF

The DMF#36513 demonstrates ANP’s success in the development of its “Plug and Play” drug delivery platform.


Merck’s pembrolizumab demonstrates improvement in distant metastasis
News | June 06, 2022

Merck’s pembrolizumab demonstrates improvement in distant metastasis

Immune-mediated events and infusion reactions were higher with KEYTRUDA (38% vs 9%, respectively).


Indian pharma market to grow at a CAGR of 12.3% to US$130 bn
News | June 04, 2022

Indian pharma market to grow at a CAGR of 12.3% to US$130 bn

PharmaLytica Expo to aid in chalking out pharma industry’s $130 Billion growth story by 2030


Innate Pharma announces IPH5201 phase 2 study in lung cancer
News | June 04, 2022

Innate Pharma announces IPH5201 phase 2 study in lung cancer

Innate to receive $5M milestone payment from AstraZeneca


Mitsubishi Tanabe Pharma America presents 48-week results from phase 3 safety clinical study of Radicava ORS
News | June 03, 2022

Mitsubishi Tanabe Pharma America presents 48-week results from phase 3 safety clinical study of Radicava ORS

Radicava ORS was approved by the U.S. Food and Drug Administration (FDA) on May 12, 2022


Digitalization of pharma labs will help in better decision making: Experts
Digitisation | June 02, 2022

Digitalization of pharma labs will help in better decision making: Experts

Besides enhancing workflow operations by connecting scientists with their lab instruments and data, digitalization holds the potential to acceleratee long-term business growth


USFDA accepts dupilumab for priority review in adults with prurigo nodularis
Drug Approval | June 01, 2022

USFDA accepts dupilumab for priority review in adults with prurigo nodularis

Dupixent would be the first and only medicine specifically indicated to treat prurigo nodularis in the U.S., if approved


FDA approves Roche’s Evrysdi for use in babies under two months with SMA
Drug Approval | June 01, 2022

FDA approves Roche’s Evrysdi for use in babies under two months with SMA

Evrysdi has proven efficacy in babies, children and adults with more than 5,000 patients treated to date


US FDA accepts new drug application filed by Avillion for AstraZeneca's PT027
Drug Approval | June 01, 2022

US FDA accepts new drug application filed by Avillion for AstraZeneca's PT027

Avillion announces expansion of partnership with AstraZeneca on PT027 and will fund and execute a new Phase 3b study